Literature DB >> 10408862

c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates.

A Mezzelani1, L Alasio, C Bartoli, M G Bonora, M A Pierotti, F Rilke, S Pilotti.   

Abstract

The detection of specific genetic alterations in breast cancer is useful for diagnosing, predicting prognosis and planning preoperative treatment. c-erbB2/neu overexpression is usually detected by immunocytochemistry (ICC), although this technique is neither completely reproducible nor highly reliable, owing to specimen and methodologic variability and antibody sensitivity. Here, we combine two well-established techniques, fine-needle aspiration (FNA) and fluorescence in situ hybridization (FISH), to detect c-erbB2/neu amplification in patients candidate to primary chemotherapy and, in part, previously analysed for c-erbB2/neu overexpression. Sixty smears from FNA were used to simultaneously detect c-erbB2/neu and chromosome 17 centromere. FISH was successful in 58 cases and detected 24 amplified cases, three of which were negative by immunophenotyping, 28 negative cases, with evidence of two normal c-erbB2/neu/signals, two cases with deletion of c-erbB2/neu, and four cases with polysomy, thus providing more reliable and informative results than ICC. This study underlines the advantages offered by the FNA and FISH combination which are two rapid, reliable, simple and informative techniques, to analyse one of the most important genetic markers for predicting prognosis and chemotherapy planning for breast carcinoma in particular in the light of the recently proposed trials of primary chemotherapy.

Entities:  

Mesh:

Year:  1999        PMID: 10408862      PMCID: PMC2362342          DOI: 10.1038/sj.bjc.6690387

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  35 in total

1.  High-resolution mapping of human chromosome 11 by in situ hybridization with cosmid clones.

Authors:  P Lichter; C J Tang; K Call; G Hermanson; G A Evans; D Housman; D C Ward
Journal:  Science       Date:  1990-01-05       Impact factor: 47.728

2.  The subcellular localization of the neu protein in human normal and neoplastic cells.

Authors:  C R De Potter; J Quatacker; G Maertens; S Van Daele; C Pauwels; C Verhofstede; W Eechaute; H Roels
Journal:  Int J Cancer       Date:  1989-12-15       Impact factor: 7.396

3.  Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors.

Authors:  F Rilke; M I Colnaghi; N Cascinelli; S Andreola; M T Baldini; R Bufalino; G Della Porta; S Ménard; M A Pierotti; A Testori
Journal:  Int J Cancer       Date:  1991-08-19       Impact factor: 7.396

4.  C-erbB-2 expression and DNA ploidy status in breast cancer cells obtained by fine needle aspiration (FNA).

Authors:  G Troncone; P Zeppa; F Fulciniti; G Di Benedetto; M A Lobresco; B De Divitiis; A Vetrani; L Palombini
Journal:  Cytopathology       Date:  1993       Impact factor: 2.073

5.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.

Authors:  S W Lowe; H E Ruley; T Jacks; D E Housman
Journal:  Cell       Date:  1993-09-24       Impact factor: 41.582

6.  Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

Authors:  B A Gusterson; R D Gelber; A Goldhirsch; K N Price; J Säve-Söderborgh; R Anbazhagan; J Styles; C M Rudenstam; R Golouh; R Reed
Journal:  J Clin Oncol       Date:  1992-07       Impact factor: 44.544

7.  ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization.

Authors:  O P Kallioniemi; A Kallioniemi; W Kurisu; A Thor; L C Chen; H S Smith; F M Waldman; D Pinkel; J W Gray
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

Review 8.  Chromosome aberrations and cancer.

Authors:  E Solomon; J Borrow; A D Goddard
Journal:  Science       Date:  1991-11-22       Impact factor: 47.728

9.  Elimination of extrachromosomally amplified MYC genes from human tumor cells reduces their tumorigenicity.

Authors:  D D Von Hoff; J R McGill; B J Forseth; K K Davidson; T P Bradley; D R Van Devanter; G M Wahl
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

10.  Aneuploidy fraction but not DNA index is important for the prognosis of patients with stage I and II breast cancer--10-year results.

Authors:  M F Gnant; G H Blijham; A Reiner; M Schemper; M Reynders; B Schutte; C van Asche; G Steger; R Jakesz
Journal:  Ann Oncol       Date:  1993-09       Impact factor: 32.976

View more
  5 in total

Review 1.  Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response.

Authors:  Monica M Reinholz; Amy K Bruzek; Daniel W Visscher; Wilma L Lingle; Matthew J Schroeder; Edith A Perez; Robert B Jenkins
Journal:  Lancet Oncol       Date:  2009-03       Impact factor: 41.316

Review 2.  Diagnostic value of fine-needle aspiration biopsy for breast mass: a systematic review and meta-analysis.

Authors:  Ying-Hua Yu; Wei Wei; Jian-Lun Liu
Journal:  BMC Cancer       Date:  2012-01-25       Impact factor: 4.430

3.  Role of hormonal risk factors in HER2-positive breast carcinomas.

Authors:  A Balsari; P Casalini; R Bufalino; F Berrino; S Ménard
Journal:  Br J Cancer       Date:  2003-04-07       Impact factor: 7.640

Review 4.  The diagnosis and management of pre-invasive breast disease: the role of new diagnostic techniques.

Authors:  Ashutosh Nerurkar; Peter Osin
Journal:  Breast Cancer Res       Date:  2003-10-09       Impact factor: 6.466

5.  FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.

Authors:  M Yoshimoto; I W Cunha; R A Coudry; F P Fonseca; C H Torres; F A Soares; J A Squire
Journal:  Br J Cancer       Date:  2007-08-14       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.